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Abstract
During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-
adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The
test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients.
An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The
proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared
with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included
1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated.
The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval
(CI)=35–93%; P=0.007) and 87% (95% CI=78–92%; P,0.001) for individuals less than 14 years of age and 70% (95%
CI=245%–94%, P=0.13) and 74% (95% CI=64–82%; P,0.001) for individuals above the age of 14. Both methods yielded
similar VE in both age groups; and VE for the younger age group seemed to be higher.
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Introduction
Phase 6 of the 2009 pandemic caused by the influenza virus A/
(H1N1) 2009 (pIV) started with the announcement of the World
Health Organization on June 11, 2009. For countries of the
Northern hemisphere, including Germany, a vaccine became
available after the autumn wave had already started. In Germany
for the most part of the autumn wave, only one type of vaccine was
available which was an egg-based vaccine containing 3.75 mg
hemagglutinine as antigenic component and the adjuvant AS03.
Prior tothe pandemic itwas anticipated that a pandemic vaccine -
even when adjuvanted - needs to be given twice to induce protective
immunity [1]. However, tests with the pandemic vaccine containing
pIV antigen have shown that a single vaccine dose of 15 mg without
adjuvant may be sufficient in participants between 3 and 77 years of
age [2]. Other studies suggested that a single dose of squalen-
adjuvanted vaccine directed against pIV may induce sufficient levels
ofimmunity inadults (using3.75 mg hemagglutinine)[3] andevenin
children 6–36 months old (using 1.9 mg antigen) [4].
In Germany, the vaccine adjuvanted with the squalene AS03
became available to the population from week 44/2009 onwards.
The German standing committee for vaccination recommended
the vaccine for the entire population, prioritizing medical
personnel, persons with chronic underlying conditions and
pregnant women [5]. While initially two doses were recommended
for children up to 9 years and elderly persons, an updated
statement recommended a single dose for all age groups [6].
Recently, Orenstein has compared several methods to estimate
VE for influenzafrom observational data including the test-negative
case-control method [7]. To extend the repertoire of observational
study types incorporating the fact that the vaccination campaign
occurred concurrently with the epidemic wave we attempted to
explore another method which has not been described previously
and uses nationally reported cases of influenza only. The method is
motivated by the self-controlled case series method that has been
used in studies on vaccine safety [8].
The objective of this paper is to assess VE of the AS03-
adjuvanted pIV vaccine using two methods: first, the test-negative
case control method; second, a novel form of a case-series method.
Materials and Methods
Laboratory test-negative case-control method
For this evaluation only patient samples taken with diagnostic
intent were analysed. Due to German standards, ethics approval
and informed consent was not necessary.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e19932We used the test-negative case-control study design similar to
that described in the ECDC technical document (2009) [9]. We
obtained virologic surveillance data from the National Reference
Center for Influenza at the Robert Koch-Institute (RKI), and the
State Laboratories of Mecklenburg-Western-Pommerania (Ro-
stock), Saxonia-Anhalt (Magdeburg), Bavaria (Oberschleissheim)
and Saxonia (Dresden), Germany. Samples were provided by
physicians who swabbed patients with influenza-like illness (ILI).
Samples were accompanied by a patient-based questionnaire with
information on age, sex, state of residence, date of symptom onset,
symptoms, underlying disease (cardiovascular, respiratory, diabe-
tes) and dates of vaccination against seasonal and pandemic
influenza, if any. Cases were confirmed by reverse-transcriptase
polymerase chain reaction (RT-PCR), controls were RT-PCR
negative. Hospitalized ILI patients and test-negative patients
where swabs were taken more than four days after disease onset
were excluded. Because vaccination against pandemic influenza
virus started in week 44/2009, we restricted data analysis to
patients with illness onset between week 44/2009 and 07/2010.
For seasonal and pandemic A/H1N1 2009 influenza vaccine it has
been shown that 90% and 79% of vaccinees, respectively, had
protective antibody titres two weeks after vaccination [10,11]. We
defined therefore patients as vaccinated when more than two
weeks had passed after the date of vaccination, and as not
vaccinated when less than two weeks had passed after the date of
vaccination.
For the analysis of categorical variables we calculated odds
ratios (OR) and 95% confidence intervals (CI). We built two
models describing the effect of vaccination against pIV and other
independent factors on pIV infection, one for children (less than
14 years) and one for ‘‘adults’’ (at least 14 years). We considered as
confounders age (as numerical variable), sex, illness week and
location of residence, and included in the models those variables
that were associated with both pIV infection and vaccination and
changed the OR for vaccination by more than 5%. The final
model included only the remaining variables as well as illness
week. Statistical tests were two-sided and P values of less than 0.05
were considered statistically significant. For calculations we used
the software Stata (Stata Corporation, College Station, Texas,
USA).
Case-series method
For the case-series method we used all cases of pIV notified
through the mandatory notification system where date of disease
onset and age was known. Laboratory-confirmed cases of pIV had
to be notified by the diagnosing laboratories to the public health
system where vaccination status was investigated. Final data were
reported via state health departments to the RKI. Hospitalized
cases were not excluded, but were rare (less than 2%).
For this method we needed to define a time interval after
influenza vaccination when an immune response is beginning to
be detectable and when it is fully mounted. According to Brokstad
et al. [12] hemagglutinine antibody titers started to increase after
8–9 days after vaccination. Day 7 would thus be the ‘‘last day’’ in
the ‘‘unimmune’’ period and infection on day 7 results in illness on
average on day 8 or 9 (adding 1.5–2 days of incubation period). As
explained for the test-negative case-control method most vaccinees
develop protective antibody titres 2 weeks after vaccination
[10,11]. We assumed therefore a period of lacking protection
after vaccination until day 7 (i.e. day 9 when the day of illness
onset is used) and a period of full protection from day 14 after
vaccination.
To calculate the VE we assumed that the chance to fall ill and
get notified is a proxy for the force of infection that affects all
persons. So the cumulative force of infection that a person is
exposed to during time t is represented by the number of cases
reported during time t. We assume that the chance to be selected
for notification is similar in all vaccinated persons during the
protected and unprotected phase and we assume that the
susceptibility of the people at the time of vaccination is similar
to the susceptibility in the population. Susceptibility in the
vaccinated group changes in relation to the unvaccinated group
from the time of mounted immunity due to induced protection.
We assumed further that persons who were immunized were not
protected in the immediate time period after vaccination. Based on
these assumptions the number of reported cases in a cohort
defined by their vaccination date within a given week during any
period is a result of 1. the number of individuals exposed, 2. their
susceptibility, and 3. the cumulative risk to become ill and be
notified during that period.
As the number of individuals in each weekly vaccinated cohort
is unknown but unchanged over time, the ratio of (cumulative
force of infection during the unprotected phase/number of cases in
the weekly vaccinated cohort during this unprotected phase) to the
(cumulative force of infection during the protected phase/number
of cases from the cohort during the protected phase) indicates a
change in susceptibility which is attributed to the effect of the
vaccine.
To determine the force of infection during the unprotected
period of a cohort vaccinated in a given week we assumed that on
average people were vaccinated (and from thereon exposed to
infected cases) after Wednesday. While we calculated the exact
difference between vaccination date and illness date in days we
used weekly data to calculate the force of infection. For an
assumed 9 day unprotected period (to the day of symptom onset)
the exposure to infection for a vaccine cohort of week x would be
the number of all reported cases (vaccinated and unvaccinated) of
week x multiplied with 4/7(exposure time in week x), plus the
number of all reported cases of week (x+1) multiplied with 5/7
(exposure time in week (x+1)). For the number of cases vaccinated
in week x that occurred within the respective unprotected period
of 9 days we counted the number of cases that were vaccinated in
week x and had a date of illness onset within 9 days after the date
of vaccination. Thus, the reference value for a cohort of week x
(term 1) was:
(all reported cases of week x *4/7 + all reported cases of the
following week (x+1)* 5/7)/(number of cases during the unpro-
tected period (illness onset within 9 days after vaccination) of the
cohort vaccinated in week x)
We then performed the same calculation for the assumed
protected period which yielded the number of cases necessary to
generate a vaccinated case in the hypothetically protected period
ending with week 53/2009. The calculation for the protected
period beginning 14 days after vaccination for a weekly cohort
would be (term 2):
(sum of all reported cases with illness onset between week (x+2)
and week 53)/(number of cases during the protected period among
those vaccinated in week x with illness onset between week (x+2)
and week 53)
The ratio of both terms (term1/term2) gives the relative risk
which – under the null hypothesis – is one if the vaccine had no
effect.
For the calculation of the overall effect (pooled for all vaccinated
weekly cohorts) we assumed that the relation between the force of
infection and the generation of cases is stable over time and simply
pooled the numerator and denominator data of the respective
terms and weeks to calculate an average of the total VE
(appendix).
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week 44 (when vaccination started) to week 53 when the epidemic
virus circulation had largely ceased. Weeks where no vaccinated
case was reported neither in the unprotected nor in the protected
period, were excluded. We conducted the following two sensitivity
analyses: (a) for the determination of the force of infection we
included only cases with known age and illness onset; however,
cases with unknown vaccination status were excluded or included;
(b) the unprotected period was varied lasting for 6,7,8,9 or 11 days,
respectively (keeping the assumed protected period constant
beginning 15 days after vaccination).
The relative risks were calculated for each week of vaccination
and for two age groups (less than 14 years, 14 years or above). We
report relative risks for weekly cohorts of vaccination as well as an
overall estimate for all persons vaccinated.
Results
Laboratory test-negative case-control method
There were 6,195 samples of patients with illness onset between
week 44/2009 and 07/2010. Of these, 2,837 (46%) were positive
for pIV (Tab. 1). Information on explanatory variables was
available in 43% (underlying illness; minimum) up to 99% (age).
Median age was 12 years (interquartile range: 6–26 years).
Hundred twenty-six patients were reported to be vaccinated
against pIV. Of these, information on vaccination date was
available for 94 (75%). Among patients with vaccination date data,
the proportion of positive samples (positivity rate) dropped with
increasing interval between vaccination and disease onset. In 42
patients illness onset was later than 14 days after vaccination with
the pandemic vaccine representing 1% of patients with informa-
tion on vaccine status. Twenty-seven (64%) of the 42 patients were
aged younger than 14 years of age and 15 (36%) were 14 years or
older. For analysis of the VE, only patients could be included who
were known to be unvaccinated or who were vaccinated and
where date of vaccination was available. This was the case for
3,836 patients (Fig. 1). ILI cases with information about their
vaccination status were more likely to be children compared to ILI
cases without information about their vaccination status. Other
variables, such as sex, positivity to pIV and chronic underlying
disease were not significantly different between the two groups.
Of 1,749 pIV cases six (0.3%) were vaccinated more than 14
days before illness onset, of 2,087 test-negative individuals 36
(1.7%) were vaccinated. The six vaccinated cases were all treated
by different physicians. Four (67%) were younger than 14 years (9–
13 years), and of these 2 had an underlying chronic condition; two
(33%) were at least 14 years old (51 and 64 years), and of these,
one had a chronic underlying condition.
Table 1. Basic data used in the test-negative case-control study and the case-series study.
Data from national reference and state laboratories
(test-negative case-control method)
Data from reporting system
(case-series method)
Variable With information among those with information
N% N % N %
Lab result for pIV 6195 100% positive 2837 46% NA NA
negative 3358 54% NA NA
Vaccination against
pandemic A/(H1N1) 2009
3836 62% Vaccinated more than 14
days before illness onset
42 1% 57 0.1%
Not vaccinated or not in time 3794 99% 73229 99.9%
Vaccination against
seasonal influenza
5180 90% Vaccinated more than 14
days before illness onset
491 9% NA NA
Not vaccinated or not in time 4689 91% NA NA
Age 6156 99% 0–9 2452 40% 18877 26%
10–19 1797 29% 28634 39%
20–29 568 9% 8173 11%
30–39 437 7% 5671 8%
40–49 459 7% 6963 10%
50–59 300 5% 3715 5%
60–69 77 1% 853 1.2%
70+ 66 1% 393 0.5%
Sex 6124 99% Male 3173 52% 36628 50%
Female 2951 48% 36387 50%
Underlying disease 2653 43% Respiratory 237 9% NA NA
Cardiovascular 75 3% NA NA
Diabetes 28 1% NA NA
unspecified 141 5% NA NA
none 2172 82% NA NA
Completeness and frequency distribution of variables describing (a) the study population of patients whose sample was sent to the National Reference Center for
Influenza or to one of four state laboratories and tested for pandemic influenza virus A/(H1N1) 2009 (test-negative case-control method); and (b) characteristics of the
patients reported to the public health system (used in the case-series method); Germany, 2009/10.
doi:10.1371/journal.pone.0019932.t001
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with pIV infection with an OR of 0.17 (95% CI=0.06–0.40;
P,0.001), however, vaccination against seasonal influenza
(OR=0.91; 95% CI=0.95–1.10; P=0.34) and underlying disease
(OR=0.84; 95% CI=0.69–1.04; P value=0.10) were not.
Positivity rate differed by age. It first increased up to 10 years of
age and then declined thereafter (Fig. 2). Also male sex
(OR=1.14; 95% CI=1.03–1.26; P=0.01) was significantly
associated with pIV infection. Positivity rate varied by week of
illness onset with a plateau between week 44 up to week 52 and
declined thereafter.
After multivariate logistic regression the model for children
included the variables vaccination against pIV, age and illness
week, and the model for adults contained the variables vaccination
against pIV, age, illness week and state of residence (Tab.e 2). In
children vaccination against pIV had an OR of 0.21 (Tab. 2)
yielding an effectiveness of 79% (95% CI=35%–93%; P=0.007).
In the age group 14 years and above, vaccination against pIV had
an OR of 0.30 for an effectiveness of 70%, but this result was not
statistically significant (P=0.13; Tab. 2).
Case-series method
In the period from week 44/2009 to week 53/2009 102,454
cases with a known date of illness onset and age were reported. Of
these, vaccination status was known for 73,280 cases (71%). The
number of vaccinated cases by interval between vaccination date
and illness onset started with a peak on the first day after
vaccination and decreased then rapidly to very low numbers by
day 10–14 (Fig. 3). The distribution of the number of vaccinated
cases by age group was bimodal with one peak at the age group
11–15 years and a second at 46–50 years. Figure 4 shows the total
number of cases by week of illness onset as well as the number of
vaccinated cases by week of vaccination. The shape of the curve of
vaccinated cases by week of vaccination is similar to that of the
number of reported cases. The expected number of vaccinated
cases during their protected period (assuming that VE is 0%)
differs markedly from the curve with the actual number of
vaccinated cases during the protected period (Fig. 4).
Figure 1. Breakdown of population according to vaccination status, test-negative case-control method.
doi:10.1371/journal.pone.0019932.g001
Figure 2. Proportion of positive samples (positivity rate) by
age. Points are located at the mean of the ages in the age groups;
Germany 2009/2010.
doi:10.1371/journal.pone.0019932.g002
Effectiveness of the AS03-Adjuvanted Vaccine
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e19932The VE estimates for the different weekly cohorts is relatively
stable within the two age segments despite the low numbers of
vaccinated cases (Tab. 3; Fig. 5). In the sensitivity analysis, neither
choosing different lengths of the unprotected period (6,7,8,9 and
11 days, respectively) nor the inclusion or exclusion of cases where
the exact vaccination status is unknown (for the parameter ‘‘total
number of reported cases’’) has a marked effect on the estimated
VE. The confidence intervals of the weekly cohorts overlap. The
main influence seems to be age. Overall VE is higher in children
compared to adults. The range of the overall point estimates is 86–
89% in children and 69–75% in adults, for the weekly cohorts it
ranges from 71–90% in children and from 58–85% in adults. All
point estimates are statistically significant. Excluding people over
the age of 60 from analysis in the case-series method raises the VE
estimate by 5% for the age group 14–60 years.
Discussion
Based on data from virologic surveillance as well as from the
notifiable disease surveillance system we have found evidence for a
good clinical protective effect of the AS03-adjuvanted vaccine that
was used in Germany against pIV in autumn of 2009. This finding
is corroborated by three results: (1) The positivity rate of
vaccinated persons decreased with increasing interval between
vaccination date and illness date; (2) the number of vaccinated
cases in the database of reported cases decreased to low numbers
for those who were vaccinated more than 10–14 days before illness
onset (Fig. 2); (3) using two different data sources and two different
statistical methods have led to similar point estimates of
effectiveness in two age strata.
The dataset used for the test-negative case-control method
comprises detailed data from sentinel physicians, but the number
of vaccinated cases was small. The dataset from the mandatory
notification system - used for the case-series method - comprised in
principle data from all physicians and hospitals who diagnose pIV,
is many-fold larger but includes fewer patient parameters. Due to
these differences, not all stratifications or analyses were similarly
possible for both methods. In both datasets persons over 60 years
were rare; excluding them in the case-series method would have
led to an increase of 5% in the 14–60 year old age group
indicating a relatively lower protection in the elderly.
The test-negative case-control method was first described by
Skowronski [13] and Uphoff [14]. It provides a convenient set of
controls and can control for a number of covariates if collected. It
is based on the assumption that vaccinated patients consult their
physician with the same likelihood as non-vaccinated patients
Table 2. Multivariate logistic regression model, test-negative
case-control method.
OR Lower CL Upper CL p-value
Below 14 years
Vaccination against pIV 0.21 0.07 0.65 0.007
Age less than 11 years; per year 1.21 1.18 1.26 ,0.001
Age more than 10 years; per year 0.84 0.74 0.96 0.009
At least 14 years
Vaccination against pIV 0,30 0.06 1.45 0.13
Age 14 years and above; per year 0.97 0.96 0.98 ,0.001
Final multivariate logistic regression model of explanatory variables for
infection with pandemic influenza (pIV) controlling for illness week (below 14
years) and for illness week and state of residence (at least 14 years); laboratory
test-negative case-control method; Germany, 2009/10.
doi:10.1371/journal.pone.0019932.t002
Figure 3. Vaccinated cases by time between vaccination and Illness. Frequency of reported and vaccinated laboratory-confirmed cases of
pandemic influenza H1N1(2009) by interval between vaccination and illness onset; weeks of illness onset 44–53/2009; Germany.
doi:10.1371/journal.pone.0019932.g003
Effectiveness of the AS03-Adjuvanted Vaccine
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e19932when developing ILI and that influenza is detected with the same
likelihood if present [13]. To reduce the chance for false negative
results we restricted our analysis to test-negative ILI patients whose
samples were taken no later than 4 days after disease onset.
Because RT-PCR is highly specific (.=99%), the probability for
a false positive sample is very low.
The case-series method is applicable to routinely collected data.
Although the unprotected period was short and the number of
vaccinees among reported cases low, the method gave reasonable
results. Estimates for weekly cohorts do not differ significantly from
each other and from the estimate for the total season. Overall, VE
estimates of the weekly age group cohorts are all above 50% and it
is reassuring that they vary within a rather narrow corridor (Fig. 5).
It has to be noted that we have not weighted the estimate of the
VE for the total season because the size of the weekly cohorts was
unknown (see Fig. S1 and Appendix S1). However, even a
weighted estimate should be very similar because the weekly
estimates lie within a close range. To further refine the
methodology to calculate an overall estimate, approaches such
as those used in meta analysis, may be considered [15].
Both methods were able to take into account that the epidemic
wave evolved at the same time with the vaccination campaign. To
do this, the test-negative case-control method added illness week
into the multivariate model while the case-series method used the
number of incident reported cases by week to calculate the
proportion of expected vaccinated cases if the vaccine had no
effect. A strength of both methods is that selection processes have
limited effect because they apply equally to the entire study
population.
Vaccination against seasonal influenza was not significantly
associated with pIV infection. Several articles have published their
analyses regarding the effect of seasonal trivalent influenza on the
occurrence of pIV infection, but results were contradictory. A lack
of effect [16,17,18], a preventive effect [19,20] and even a
‘‘harmful’’ effect have all been reported [21]. With the power
available in our dataset we would have detected even a small
effect, for example if the OR for pIV would have been greater
than 1.2 or smaller than 0.8.
Because the vaccine used in Germany was a vaccine adjuvanted
by the squalen AS03 we cannot make statements about non-
adjuvanted vaccines which may have different VE than the one
used in Germany. When we attempted to compare our results with
studies on the efficacy of squalen-adjuvanted seasonal influenza
vaccines, we were unable to identify any in the published
literature. However, clinical protection against seasonal influenza
provided by inactivated, non-adjuvanted vaccines has been
reviewed by Nichol who based her assessment on several published
meta-analyses of mostly randomized controlled trials [22].
Depending on the results of different meta-analyses, effectiveness
against laboratory-confirmed influenza in children ranged from
54–65% and in younger adults (aged younger than 65 years) from
63–80%. For elderly (aged more than 60 years) the only conducted
randomized controlled trial found an efficacy of 58% [23]. With
all due caution the effectiveness presented in this paper seems to be
better for children and comparable in younger adults.
Our methods have several limitations. The case-series method is
prone to influences biasing the case count during the unprotected
period versus the protected period. This may be the case if
physicians tend to sample vaccinated persons in the two weeks
after vaccination more than in the protected period or if
vaccinated persons get vaccinated when they become aware of
influenza cases in their (private) surrounding, but are less eager to
become vaccinated when the epidemic wave has passed and the
risk has therefore diminished. Then the decision to become
Figure 4. Case-series method. Frequency of total number of cases with known age and onset of illness (grey, left y-axis), of vaccinated cases by
week of vaccination (dashed grey line; right y-axis), vaccinated cases by week of illness onset (unprotected period; dashed-dotted line; right y-axis),
vaccinated cases by week of illness onset (protected period; black line; right y-axis) and vaccinated cases by week of illness onset that would be
expected if the vaccine had no effect (protected period; dashed black line; right y-axis), Germany; week 44–53, 2009.
doi:10.1371/journal.pone.0019932.g004
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e19932vaccinated and the risk for infection in the unprotected period may
reflect to some degree not only the force of infection in the
population as a whole but particularly in their immediate
environment. However, the distribution of cases after vaccination
(Fig. 3) does not suggest that these potential biases are of
substantial magnitude.
On a similar note, we have not taken into account the dynamic
geographical course of the epidemic which also may have affected
vaccination and disease status. Here, two scenarios are possible: (i)
individuals have been vaccinated when the epidemic was
approaching (staggered vaccination), (ii) individuals have been
vaccinated when the vaccine became available (vaccination largely
at the same time). Some simple calculations simulating the first
scenario showed small deviations of about 5% of the calculated
vaccine effectiveness; however, in the scenario where most persons
were vaccinated in the first weeks when the vaccine became
available, i.e. vaccination was mainly triggered by availability of
the vaccine, would not have resulted in a different effectiveness. As
it turned out vaccination coverage remained low in Germany as
only 8% of the population was vaccinated [24]. In particular,
during the start of the campaign it was focused on priority groups,
such as health care personnel, first responders, persons with
chronic underlying diseases and pregnant women. Scenario two
seems therefore more realistic. Another way to analyse this issue
would have been to stratify by geographical region which would
have necessitated a larger number of vaccinated cases than were
available.
In the case series method it was necessary to use cut-off points
for the end of the unprotected and the beginning of the protected
period after vaccination which could be challenged. The work by
Brokstad et al. showed an increase in antibody titers 8–9 days post
vaccination [12]. After that an increase roughly following a
saturation curve can be expected resulting in protective antibody
titres in the majority of vaccinees about two weeks post vaccination
[10]. Data from recent studies confirm these findings also for the
pandemic vaccine [11,25]. To explore the influence of different
cut-off points on the VE estimates we had calculated the effect
when the unprotected period was assumed to last until day 6,7,8,9
and 11 post vaccination. Lowering the unprotected period from 9
to 6 days increased the VE stepwise to roughly 3% at day 6, and
dropped by 2% when the unprotected period was extended to 11
days. We concluded that the choice of the cut-off for the
unprotected period is minor and that the results generated by
the method are fairly robust. Nevertheless, a degree of imprecision
remained because we used weekly values for the force of infection
and the assumption that the cohort had been vaccinated by
Wednesday.
Compared to our estimates, a recent publication using the
screening method found a higher VE than presented here (97% for
persons aged 14–59 years, 83% for persons 60 years and older)
[26]. In general, the screening method may encounter difficulties
when assessing VE during an ongoing vaccination campaign
because the dynamic of the epidemic, the change of the proportion
vaccinated in the population over time and the time that
vaccinations need to take effect need to be considered. In the
above mentioned paper, the authors tried to take these issues into
account by beginning their study period three weeks after
initiation of the vaccination campaign when estimated vaccination
coverage in the population was already 4%, and coverage
increased only by an additional 3% over the next 3 months
[26]. In addition, selection processes like a lower likelihood to swab
vaccinated persons or different laboratory sensitivity for different
age groups in relation to the proportion vaccinated in these age
groups may influence the estimated VE. A case control study from
England and a European multicenter case control study showed
similar estimates than our study (71% [27] and 72% [25](impu-
tation) or 66% respectively). One study found indications for a
lower protection in the elderly [25] and the other study indicated a
higher protection in the younger age group [27], which is in line
with the results of our study. Interestingly one study indicated a
Figure 5. Vaccine effectiveness by weekly cohort. Vaccine effectiveness of pandemic AS03-adjuvanted vaccine, by weekly vaccinated cohort;
case-series method; force of infection is represented by all reported cases with available information on age, illness onset and vaccination status; for
methods: see text; up=unprotected period, pp=protected period, pv=post vaccination.
doi:10.1371/journal.pone.0019932.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e19932possible protection in the period 8 to 14 days after vaccination
which potentially may challenge the assumption of a negligible
protection in the first seven days after vaccination [25]. However
the confidence intervals of the estimation are very wide. In our
data we observed a very steep drop of cases 7 to 9 days after
vaccination (Fig. 3) suggesting that immunity starts to take effect
approximately one week after vaccination. A thorough compar-
ison of all methods and findings (including other studies) may give
more insight to explain differing results.
In conclusion both methods provided evidence for the good VE
of the AS03-adjuvanted vaccine against the pandemic virus A/
(H1N1) 2009. Should this virus remain the dominant virus or one
of the viruses circulating in the human population, this or a similar
vaccine should provide satisfactory protection against disease.
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